{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-032935","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.251826+00:00","generated_at":"2026-05-14T19:57:25.528520+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vistagen completes PALISADE-4 Phase 3 patient visits; topline data due Q2 2026","bullets":["Last patient completed randomized portion of Phase 3 trial for fasedienol acute treatment of social anxiety disorder.","Topline results for PALISADE-4 expected in second quarter 2026.","FDA has no comments on refined statistical analysis plan incorporating pre-dose SUDS baseline covariate.","Open-label extension remains ongoing; fasedienol has FDA Fast Track designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-032935","json":"https://secwatch.observer/filing/0001628280-26-032935.json","markdown":"https://secwatch.observer/filing/0001628280-26-032935.md","text":"https://secwatch.observer/filing/0001628280-26-032935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026032935/0001628280-26-032935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026032935/vtgn-20260508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T19:57:25.528520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}